RU2019130404A - New recombinant analogue of prolonged-release growth hormone - Google Patents

New recombinant analogue of prolonged-release growth hormone Download PDF

Info

Publication number
RU2019130404A
RU2019130404A RU2019130404A RU2019130404A RU2019130404A RU 2019130404 A RU2019130404 A RU 2019130404A RU 2019130404 A RU2019130404 A RU 2019130404A RU 2019130404 A RU2019130404 A RU 2019130404A RU 2019130404 A RU2019130404 A RU 2019130404A
Authority
RU
Russia
Prior art keywords
growth hormone
prolonged
seq
recombinant
new recombinant
Prior art date
Application number
RU2019130404A
Other languages
Russian (ru)
Other versions
RU2019130404A3 (en
RU2753191C2 (en
Inventor
Вагиф Али оглы Гасанов
Александр Федорович Шевалье
Ольга Владимировна Симонова
Илья Борисович Мерцалов
Дина Александровна Куликова
Original Assignee
Федеральное государственное бюджетное учреждение науки Институт Биологии Развития им. Н.К. Кольцова Российской Академии Наук
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение науки Институт Биологии Развития им. Н.К. Кольцова Российской Академии Наук filed Critical Федеральное государственное бюджетное учреждение науки Институт Биологии Развития им. Н.К. Кольцова Российской Академии Наук
Priority to RU2019130404A priority Critical patent/RU2753191C2/en
Publication of RU2019130404A publication Critical patent/RU2019130404A/en
Publication of RU2019130404A3 publication Critical patent/RU2019130404A3/ru
Application granted granted Critical
Publication of RU2753191C2 publication Critical patent/RU2753191C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)

Claims (5)

1. Рекомбинантный полипептид, обладающий агонистической активностью в отношении рецептора гормона роста человека, характеризующийся тем, что имеет аминокислотную последовательность SEQ ID:1.1. A recombinant polypeptide having human growth hormone receptor agonist activity, characterized in that it has the amino acid sequence of SEQ ID: 1. 2. Рекомбинантный пептид по п. 1, в котором в качестве участка, способствующего димеризации пептида, содержится любая аминокислотная последовательность, обладающая способностью образовывать димеры параллельных альфа-спиралей.2. A recombinant peptide according to claim 1, wherein any amino acid sequence capable of forming parallel alpha-helix dimers is contained as the site for promoting the dimerization of the peptide. 3. Рекомбинантный пептид по п. 1, в котором в качестве последовательности, обеспечивающей сродство с холестерином на мембране клетки, выступает последовательность, содержащая холестерин-связывающий консенсусный мотив Leu/Val-X(l-5)-Tyr-X(l-5)-Arg/Lys.3. Recombinant peptide according to claim 1, in which the sequence that provides affinity for cholesterol on the cell membrane is a sequence containing a cholesterol-binding consensus motif Leu / Val-X (l-5) -Tyr-X (l-5 ) -Arg / Lys. 4. Штамм-продуцент Е. coli, экспрессирующий рекомбинантный пептид SEQ ID:1.4. Producer strain E. coli expressing the recombinant peptide SEQ ID: 1. 5. Фармацевтическая композиция на основе пептида SEQ ID:1 для подкожного, внутримышечного или ректального введения.5. Pharmaceutical composition based on peptide SEQ ID: 1 for subcutaneous, intramuscular or rectal administration.
RU2019130404A 2019-09-26 2019-09-26 New recombinant growth hormone analogue with prolonged activity RU2753191C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2019130404A RU2753191C2 (en) 2019-09-26 2019-09-26 New recombinant growth hormone analogue with prolonged activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019130404A RU2753191C2 (en) 2019-09-26 2019-09-26 New recombinant growth hormone analogue with prolonged activity

Publications (3)

Publication Number Publication Date
RU2019130404A true RU2019130404A (en) 2021-03-26
RU2019130404A3 RU2019130404A3 (en) 2021-03-26
RU2753191C2 RU2753191C2 (en) 2021-08-12

Family

ID=75159003

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019130404A RU2753191C2 (en) 2019-09-26 2019-09-26 New recombinant growth hormone analogue with prolonged activity

Country Status (1)

Country Link
RU (1) RU2753191C2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209055A (en) * 2013-03-11 2015-12-30 阿穆尼克斯运营公司 Treatment of pediatric growth hormone deficiency with human growth hormone analogues
RU2016143415A (en) * 2016-11-03 2018-05-03 Общество С Ограниченной Ответственностью "Биохарт" RECOMBINANT PEPTIDE OF LONG-TERM ACTION, INHIBITING HIV FUSION WITH TARGET CELL
RU2656140C2 (en) * 2016-11-14 2018-05-31 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Method for obtaining a hybrid protein containing a fused protein analogue of an interferon gamma conjugated with oligosaccharide

Also Published As

Publication number Publication date
RU2019130404A3 (en) 2021-03-26
RU2753191C2 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
RU2678134C2 (en) Insulin-incretin conjugates
RU2012101274A (en) Glucagon Compounds Active Against the GIP Receptor
JP2015504052A5 (en)
RU2011134596A (en) OXYNTHOMODULINE ANALOGUES
JP2014508510A5 (en)
AU2013337250B2 (en) Long-acting single-chain insulin analogues
DE112006000677A5 (en) Recombinant expression of proteins in a disulfide-bonded, two-chain form
FI3256579T3 (en) Cysteine protease
NZ596778A (en) Glucose-regulating polypeptides and methods of making and using same
HRP20140616T1 (en) Oxyntomodulin peptide analogue
EA201100038A1 (en) GLUCAGON RECEPTOR COAGONISTS / GLP-1-RECEPTOR
US11911443B2 (en) Fusion proteins with extended serum half life
Chorev et al. Modifications of position 12 in a parathyroid hormone and parathyroid hormone-related protein: toward the design of highly potent antagonists
NO304267B1 (en) Analogous Process for Preparation of a Therapeutically Active Specific Platelet Aggregation Inhibitor (PAI) Peptide
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
KR20100029195A (en) Bifunational fusion proteins of the alpha-melanocyte stimulating hormone(alpha-msh) and atrial natriuretic protein(anp) and uses in hyperstension and acute kidney injury
AR064555A1 (en) WT1 PEPTIDE RESTRICTED TO HLA-A * 1101 AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SAME
CN102083855A (en) New insulin analogues of prolonged activity
MX2011001028A (en) Truncated analogues of glucose-dependent insulinotropic polypeptide.
RU2012123642A (en) INSULIN ANALOGUES CONTAINING CHLORINATED AMINO ACIDS
CA2961037A1 (en) Biphasic single-chain insulin analogues
SI2797950T1 (en) Anticancer fusion protein
RU2015103816A (en) CELLING PEPTIDES IN THE CELL, THE TARGET OF WHICH IS THE eIF4E
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
AU2018216033A1 (en) Peptide modulators of the interaction between human C-peptide and human elastin receptor for therapeutic use

Legal Events

Date Code Title Description
HC9A Changing information about inventors